TROMBOEMBOLISMO PULMONAR: Tratamiento del tromboembolismo pulmonar sintomático con rivaroxabán oral

Carlos Sánchez, MD.; Darío Londoño Trujillo, MD., MSc.

doi:10.30789/rcneumologia.v24.n4.2012.143

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

TROMBOEMBOLISMO PULMONAR: Tratamiento del tromboembolismo pulmonar sintomático con rivaroxabán oral

Published 2013-12-28

Open | Download

PDF (Spanish) FLIP

Issue

Vol. 24 No. 4 (2012)

Section

Journal clubs

How to Cite

Sánchez, MD. C, Londoño Trujillo, MD., MSc. D. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

rev. colomb. neumol. [Internet]. 2013 Dec. 28 [cited 2025 Jul. 5];24(4):205-7. Disponible en: https://doi.org/10.30789/rcneumologia.v24.n4.2012.143

DOI

https://doi.org/10.30789/rcneumologia.v24.n4.2012.143

Dimensions

PlumX

license

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Carlos Sánchez, MD.

Hospital Universitario San Ignacio, Pontificia Universidad Javeriana. Bogotá, Colombia.

Darío Londoño Trujillo, MD., MSc.

Hospital Universitario San Ignacio, Pontificia Universidad Javeriana. Bogotá, Colombia.

Show authors biography

Carlos Sánchez, MD.,

Internista, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana. Bogotá, Colombia.

Darío Londoño Trujillo, MD., MSc.,

Internista, Neumólogo, Jefe de Neumología, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana. Bogotá, Colombia.

Article visits 504 | PDF visits 2642

Downloads

Download data is not yet available.

Silverstein MD, Heit JA. Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 111. Trends in the incidence of deep veln thrombosis and pulmonary embolism: a 25-year population-based study. Arch lntern Med. 1998; 158: 585-93.
Oger E. lncidence of venous thromboembolism: a community-based study in western France Thromb Haemost 2000; 83: 657-60.
Eichinger S, et al. Thrombosis or pulmonary embolism: the Vienna prediction model risk assessment of recurrence in patients with unprovoked deep vein. Circulalion 2010; 121: 1630-1636.
Douketis JO et al. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann lntern Med. 2007; 147: 766-774.
Ridker PM, et al. Long-term, low-lntensity warfarin therapy for the prevention of recurrent venous thromboembollsm. N Engl J Med. 2003; 348: 1425-1434.
Kearon C. Kahn SR. Agnelli G. Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease· American College of Chest Physicians Evidence-Based Clinical Practice Gurdelrnes (8th Edition). Chest. 2008; 133: 4548-5458
Büller HR, GallusAS, Pillion G, Prins MH, Raskob GE. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary ernbolism: a randomised, double-blind, doubfe-dummy, non-inferiority trial. Lancet 2012; 379: 123-9.
The van Gogh lnvestigators. ldraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007; 357: 1094-104.
Agnelli G, Buller HR, Cohen A, et al. apixaban for extended treatment of venous thromboembollsm. N Engl J Med. 2013; 368: 699-708.